To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Recommended dose
Dosing precautions and considerations
Administration

TEZSPIRE^® (tezepelumab):
Recommended dose¹

TEZSPIRE^® is an add-on maintenance treatment for adults and adolescents aged 12 years and older with severe asthma. It should not be used to treat acute symptoms or asthma exacerbations.

Dosing once every 4 weeks¹

TEZSPIRE^® is available as a pre-filled pen or a pre-filled syringe¹

Pre-filled pen or pre-filled syringe (210 mg)

For both devices:¹

The recommended dose is 210 mg every 4 weeks
The injection is subcutaneous

Show your patients how to administer TEZSPIRE^®

TEZSPIRE^® (tezepelumab): Dosing precautions and considerations¹

Do not prescribe TEZSPIRE^® if the patient is allergic to the drug or its excipients.
Do not prescribe TEZSPIRE^® if the patient is younger than 12 years old.
Avoid the use of TEZSPIRE^® during pregnancy.

For more information, please review the TEZSPIRE^® Product Monograph or the TEZSPIRE^® Safety Profile

TEZSPIRE^® (tezepelumab) dose adjustments¹

No dose adjustments are required for the following patient groups, based on population pharmacokinetic modeling:

Geriatric patients ≥ 65 years of age

Patients with renal impairments

Patients with hepatic impairments

TEZSPIRE^® (tezepelumab) missed doses¹

If a dose is missed, administer the dose as soon as possible. Continue dosing on the usual day of administration. If the next dose is imminent, administer TEZSPIRE^® without delay.

TEZSPIRE^® (tezepelumab) overdose¹

TEZSPIRE^® doses of up to 280 mg SC every 2 weeks and doses of up to 700 mg IV every 4 weeks have been administered clinically without evidence of dose-related toxicities.

If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

For management of suspected drug overdose, contact your regional poison control centre.

TEZSPIRE^®(tezepelumab): Administration¹

Patients or their caregivers may administer TEZSPIRE^® after being trained in SC injection technique (in the thigh or abdomen, except for the 5 cm (2 inches) around the navel).

Alternatively, a healthcare professional may administer the injection (the upper arm can be used in this instance).

Guidance for patients on TEZSPIRE^®administration¹

Prior to administration, remove the carton from the refrigerator and allow TEZSPIRE^® to reach room temperature (~60 minutes).

TEZSPIRE^® can stay at room temperature (20˚C to 25˚C) for up to 30 days after being taken out of the refrigerator. Once it reaches room temperature, it cannot be put back in the refrigerator.

Do not shake, freeze, or expose the TEZSPIRE^® solution to light.

TEZSPIRE^® is clear to opalescent, colourless to light yellow. Do not inject TEZSPIRE^® if the liquid is cloudy, discoloured, or if it contains larger particles or foreign particulate matter.

TEZSPIRE^® should be injected into the thigh or abdomen, except for the 5 cm (2 inches) around the navel. It is recommended to rotate the injection site with each injection.

TEZSPIRE^® should not be injected into areas where the skin is tender, bruised, erythematous, or hardened.

Patient instructions for TEZSPIRE^® administration¹

Step 1

Instruct patients to wash their
hands and clean the injection site

Step 2

Direct them to position the pen at the
injection site, against the skin at a 90˚ angle

Step 3

Once they press down firmly,
they will hear the first ‘click’

Step 4

Then, advise them to hold down
firmly for ~15 seconds, until they
hear a second ‘click’

Step 5

After completing the injection,
instruct them to lift the pre-filled
pen straight up

Step 6

Direct your patient on how to check
the viewing window to ensure all the
medicine has been injected.

If the orange plunger rod does not fill
the viewing window, they may not
have received the full dose.

If this happens or if they have any
other concerns, advise them to
contact yourself or other members on
their healthcare team.

Download the Pre-Filled Pen Journey Guide to give to
your patients to help them with administration.

Download the guide

TEZSPIRE^® (tezepelumab) composition and packaging¹

TEZSPIRE^® is a sterile, preservative-free solution intended for SC injection. It is available as a single-use pre-filled pen or pre-filled syringe. Each pre-filled pen or syringe contains a solution of 210 mg of TEZSPIRE^® in 1.91 mL (110 mg/mL).

Please refer to the Product Monograph for the complete dosing and
administration information.

IV, intravenous; SC, subcutaneous

Reference:

AstraZeneca Canada Inc. TEZSPIRE^® Product Monograph. 2024.

Last reviewed: Sept 2024

TEZSPIRE® (tezepelumab) Dosing & Administration

TEZSPIRE® (tezepelumab): Recommended dose1

Show your patients how to administer TEZSPIRE®

TEZSPIRE® (tezepelumab): Dosing precautions and considerations1

TEZSPIRE® (tezepelumab) dose adjustments1

TEZSPIRE® (tezepelumab) missed doses1

TEZSPIRE® (tezepelumab) overdose1

TEZSPIRE® (tezepelumab): Administration1

Guidance for patients on TEZSPIRE® administration1

Patient instructions for TEZSPIRE® administration1

Step 1 Instruct patients to wash their hands and clean the injection site

Step 2 Direct them to position the pen at the injection site, against the skin at a 90˚ angle

Step 3 Once they press down firmly, they will hear the first ‘click’

Step 4 Then, advise them to hold down firmly for ~15 seconds, until they hear a second ‘click’

Step 5 After completing the injection, instruct them to lift the pre-filled pen straight up

TEZSPIRE® (tezepelumab) composition and packaging1 TEZSPIRE® is a sterile, preservative-free solution intended for SC injection. It is available as a single-use pre-filled pen or pre-filled syringe. Each pre-filled pen or syringe contains a solution of 210 mg of TEZSPIRE® in 1.91 mL (110 mg/mL).

TEZSPIRE® (tezepelumab) composition and packaging1

TEZSPIRE® is a sterile, preservative-free solution intended for SC injection. It is available as a single-use pre-filled pen or pre-filled syringe. Each pre-filled pen or syringe contains a solution of 210 mg of TEZSPIRE® in 1.91 mL (110 mg/mL).

Blueprint HCP Portal

TEZSPIRE^® (tezepelumab) Dosing & Administration